倍轻松介绍，面对消费场景多元化趋势，倍轻松通过模式创新与跨界合作开拓新增长空间。2025年，公 司推出"轻松一刻"健康管理品牌，构建"自研科技产品+人工按摩+艾灸理疗"的复合型业务模式，以速效 按摩服务与产品销售转化相结合的方式培育新增长点。截至2025年10月30日，该品牌已在深圳、广州、 西安、重庆、成都等城市落地15家门店，成效初显。 在跨界合作领域，倍轻松把握新能源汽车产业机遇，聚焦车载健康场景布局，与比亚迪（002594）、奇 瑞集团等头部车企达成战略合作。依托个人健康领域的技术积累，系统性地拓展至移动出行空间，为自 身开辟出一条坚实而富有潜力的增长渠道。 倍轻松还积极响应社会老龄化趋势，前瞻布局银发经济赛道。公司已有13款产品入选深圳市民政局2024 年智能居家适老化改造消费提升专项活动产品清单。公司表示，未来将进一步深化适老化产品研发与创 新，打造更贴合老年人使用习惯的智能健康产品，为业绩增长注入新动能。 此外，通过与阿里云、百度等科技企业合作，倍轻松See5k系列、数字人交互等技术成果已实现落地， 有助于提升用户体验与按摩精准度。据了解，公司目前正与更多行业头部企业展开深度合作，持续引入 前沿 ...

Group 1 - The core viewpoint of the article highlights that Shenzhen Beilingsong Technology Co., Ltd. anticipates a net profit loss of 84 million to 105 million yuan for the fiscal year 2025, attributed to strategic adjustments and upgrades within the company [1] - The intelligent massage device industry is undergoing a critical period of high-quality transformation, facing intensified competition and evolving consumer demands towards efficacy and experience [1] - The company is focusing on a "Traditional Chinese Medicine × Technology" core strategy, emphasizing technological research and development, global expansion, and innovative business models to strengthen its development foundation [1] Group 2 - On the technology front, the company is concentrating on AI integration to build core competitiveness, upgrading its Traditional Chinese Medicine constitution identification model, and collaborating with major tech firms to enhance user experience and product precision [2] - The company is expanding its sales network in Southeast Asia and the Middle East, with plans to open 10 to 20 new stores in Southeast Asia by 2026, leveraging FDA-certified laser hair care technology to penetrate high-end markets in Europe and the U.S. [2] - The company is innovating its business model by launching the "Easy Moment" brand in 2025, which combines products with massage and moxibustion, and has already established 15 stores in various cities [2] Group 3 - The company is leveraging "Traditional Chinese Medicine × Technology" as a driving force, continuously broadening its growth boundaries and injecting momentum for long-term high-quality development [3]

Core Viewpoint - The company, Beiliang (688793.SH), anticipates a net profit attributable to shareholders of between -105 million to -84 million yuan for the fiscal year 2025, primarily due to strategic adjustments and upgrades in response to industry changes [1] Group 1: Industry Transition and Company Strategy - The smart massage device industry is undergoing a critical transition towards high-quality development, with intensified competition and evolving consumer demands focusing on efficacy and experience [1] - Beiliang's recent performance fluctuations reflect the objective realities of this industry transition, as the company actively adapts to both industry and operational changes [1] - The company is committed to its core strategy of "Traditional Chinese Medicine × Technology," focusing on technological research and development, global expansion, and innovative business models to enhance quality and efficiency [1] Group 2: AI Integration and Product Development - Beiliang is integrating AI as a core direction in product development, combining traditional wellness wisdom with modern technology [2] - The upgraded Chinese constitution identification model, along with AI analysis modules for tongue and pulse, will enable real-time constitution reports based on data from smart wearable devices [2] - Collaborations with tech giants like Alibaba Cloud and Baidu have led to the successful implementation of technologies that enhance user experience and massage precision [2] Group 3: Global Expansion and Brand Development - The company is advancing its globalization strategy by building a comprehensive sales network that integrates online and offline channels, focusing on Southeast Asia and the Middle East [3] - Plans for 2026 include opening 10-20 new offline stores in Southeast Asia, expanding successful models from Thailand to Indonesia and Vietnam [3] - Participation in international exhibitions, such as CES, showcases new products like the AIR3 smart massager and See7R eye massager, enhancing brand visibility and global market penetration [3] Group 4: Innovative Business Models and Growth Opportunities - Beiliang is launching the "Easy Moment" health management brand in 2025, combining self-developed technology products with manual massage and moxibustion therapy to create a hybrid business model [4] - Strategic partnerships with leading automotive companies like BYD and Chery are being formed to explore health solutions in the automotive sector, opening new growth channels [4] - The company is also addressing the aging population by developing products tailored for elderly users, with 13 products already included in a government initiative for smart home upgrades [4] Group 5: Long-term Development and Market Positioning - Through the integration of "Traditional Chinese Medicine × Technology" and diverse business models, Beiliang is continuously expanding its growth boundaries and strengthening its brand presence in both domestic and international markets [5]

Core Insights - The company reported a decline in both revenue and net profit for the first half of 2025, with revenue at 385 million yuan, down 36.22% year-on-year, and a net loss of 36.11 million yuan, down 238.19% year-on-year [3][4] - The company has experienced 11 consecutive quarters of losses since 2022, with the last four quarters also showing negative results [10] - The company announced that its unremedied losses have reached one-third of its paid-in capital, necessitating a temporary shareholders' meeting as per company law [6][7] Financial Performance - In Q2, the company’s revenue was 188 million yuan, a year-on-year decline of 39.42%, with a net loss of 34.28 million yuan, down 425.76% year-on-year [4] - The overall gross margin improved to 62.63%, an increase of 0.81 percentage points compared to the same period last year, attributed to cost reduction efforts [4] - Sales expenses decreased by 27.15% to 216 million yuan, with promotional expenses dropping by 43.65% from 114 million yuan to 63.73 million yuan [4] Cash Flow and Operational Challenges - Cash received from sales and services fell to 440 million yuan, down 36.08% year-on-year, leading to a negative net cash flow from operating activities of 20.87 million yuan, a decrease of 135.32% [5][6] - The company cited macroeconomic fluctuations, structural changes in consumer behavior, and intensified industry competition as primary reasons for its financial struggles [7] Strategic Initiatives - The company aims to leverage technology in health, promoting a "Chinese medicine × technology" strategy, and plans to enhance its overseas market presence [11][12] - Despite these initiatives, revenue from high-end products has been under pressure, with significant declines across various product categories [12][13] - The overseas business also faced challenges, with revenue down 39.32% to 19.87 million yuan and a gross margin decrease of 2.48 percentage points [13]